CD45 isoforms on human CD4+ T-cell subsets - 11/09/11
M.-C. Shanafelt was supported by a Syntex Post-Doctoral fellowship. R. Lahesmaa was supported by grants from the Finnish Academy, Finnish Cultural Foundation, Rheumatism Foundation, and the Myasthenia Gravis Foundation. DNAX Research Institute of Molecular and Cellular Biology is supported by Schering-Plough Corporation.
Abstract |
We have examined the level of surface expression and functional properties of leukocyte function associated antigen-1, very late antigen-4, and CD45 isoforms on a panel of human CD4+ T-cell clones representative of TH0, TH1, and TH2 cells. There were no qualitative differences in the expression of these antigens among the three types of CD4+ T-cell clones. However, CD45RB was the only CD45 isoform that provided a costimulatory signal in a solid-phase antibody-induced cellular proliferation assay. Additionally, the antigen-induced proliferative response of T-cell clones was inhibited by soluble anti-CD45RO and anti-CD45RB antibodies. Our results suggest that CD45 isoforms differentially provide costimulatory signals to T cells. However, the ability of each CD45 isoform to provide a costimulatory signal does not differ among the TH0, TH1, or TH2 T-cell populations. (J ALLERGY CLIN IMMUNOL 1996;98:433-40.)
Le texte complet de cet article est disponible en PDF.Keywords : CD45 isoforms, T-cell subsets, costimulatory molecules
Abbreviations : LFA:, mAb:, VLA:
Plan
| From aThe Department of Leukocyte Biology, Syntex Research (at present Roche Bioscience), Palo Alto; bDepartment of Human Immunology, DNAX Research Institute, Palo Alto; cDepartment of Neurology and Neurological Sciences, Stanford University Medical Center, Stanford; and dDivision of Allergy and Immunology, Department of Medicine, University of California at San Francisco, San Francisco. |
|
| Reprint requests: Riitta Lahesmaa, Roche Bioscience, M/S S3-9, 3401 Hillview Ave., Palo Alto, CA 94303. |
|
| 0091-6749/96 $5.00 + 0 1/1/70623 |
Vol 98 - N° 2
P. 433-440 - août 1996 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
